162 related articles for article (PubMed ID: 16718617)
1. A specific picomolar hybridization-based ELISA assay for the determination of phosphorothioate oligonucleotides in plasma and cellular matrices.
Wei X; Dai G; Marcucci G; Liu Z; Hoyt D; Blum W; Chan KK
Pharm Res; 2006 Jun; 23(6):1251-64. PubMed ID: 16718617
[TBL] [Abstract][Full Text] [Related]
2. Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia.
Dai G; Chan KK; Liu S; Hoyt D; Whitman S; Klisovic M; Shen T; Caligiuri MA; Byrd J; Grever M; Marcucci G
Clin Cancer Res; 2005 Apr; 11(8):2998-3008. PubMed ID: 15837754
[TBL] [Abstract][Full Text] [Related]
3. Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma.
Yu RZ; Baker B; Chappell A; Geary RS; Cheung E; Levin AA
Anal Biochem; 2002 May; 304(1):19-25. PubMed ID: 11969184
[TBL] [Abstract][Full Text] [Related]
4. Determination of cellular uptake and intracellular levels of Cenersen (Aezea(®), EL625), a p53 antisense oligonucleotide in acute myeloid leukemia cells.
Alachkar H; Xie Z; Marcucci G; Chan KK
J Pharm Biomed Anal; 2012 Dec; 71():228-32. PubMed ID: 22944355
[TBL] [Abstract][Full Text] [Related]
5. Development of a novel scintillation proximity competitive hybridization assay for the determination of phosphorothioate antisense oligonucleotide plasma concentrations in a toxicokinetic study.
de Serres M; McNulty MJ; Christensen L; Zon G; Findlay JW
Anal Biochem; 1996 Jan; 233(2):228-33. PubMed ID: 8789723
[TBL] [Abstract][Full Text] [Related]
6. A combined solid phase extraction/capillary gel electrophoresis method for the determination of phosphorothioate oligodeoxynucleotides in biological fluids, tissues and feces.
Wu LX; Lu DD; Zhou Z; Zhang HY; Zhang YL; Wang SQ
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Feb; 877(4):361-8. PubMed ID: 19131282
[TBL] [Abstract][Full Text] [Related]
7. Characterization and quantification of Bcl-2 antisense G3139 and metabolites in plasma and urine by ion-pair reversed phase HPLC coupled with electrospray ion-trap mass spectrometry.
Dai G; Wei X; Liu Z; Liu S; Marcucci G; Chan KK
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Oct; 825(2):201-13. PubMed ID: 16111926
[TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis of phosphorothioate oligonucleotides in biological fluids using direct injection fast anion-exchange chromatography and capillary gel electrophoresis.
Bourque AJ; Cohen AS
J Chromatogr B Biomed Appl; 1994 Dec; 662(2):343-9. PubMed ID: 7719488
[TBL] [Abstract][Full Text] [Related]
9. Determination of antisense phosphorothioate oligonucleotides and catabolites in biological fluids and tissue extracts using anion-exchange high-performance liquid chromatography and capillary gel electrophoresis.
Chen SH; Qian M; Brennan JM; Gallo JM
J Chromatogr B Biomed Sci Appl; 1997 Apr; 692(1):43-51. PubMed ID: 9187382
[TBL] [Abstract][Full Text] [Related]
10. A competitive enzyme hybridization assay for plasma determination of phosphodiester and phosphorothioate antisense oligonucleotides.
Deverre JR; Boutet V; Boquet D; Ezan E; Grassi J; Grognet JM
Nucleic Acids Res; 1997 Sep; 25(18):3584-9. PubMed ID: 9278477
[TBL] [Abstract][Full Text] [Related]
11. G3139 induces cell death by caspase-dependent and -independent apoptosis on human melanoma cell lines.
Nakamura S; Inui M; Kamei T; Nakase M; Okumura K; Tagawa T
Oncol Rep; 2006 Jun; 15(6):1563-8. PubMed ID: 16685396
[TBL] [Abstract][Full Text] [Related]
12. Enzyme-linked bridging assay method for the quantification of oligonucleotide-based drugs in biological matrices.
Fu J; Sun Y; Xia S; Dong L; Wang Q; Ou L; Shen X; Lv Z; Song H
Nucleic Acid Ther; 2011 Dec; 21(6):403-13. PubMed ID: 22059489
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
Marcucci G; Stock W; Dai G; Klisovic RB; Liu S; Klisovic MI; Blum W; Kefauver C; Sher DA; Green M; Moran M; Maharry K; Novick S; Bloomfield CD; Zwiebel JA; Larson RA; Grever MR; Chan KK; Byrd JC
J Clin Oncol; 2005 May; 23(15):3404-11. PubMed ID: 15824414
[TBL] [Abstract][Full Text] [Related]
14. Determination of GTI-2040, a novel antisense oligonucleotide, in human plasma by using HPLC combined with solid phase and liquid-liquid extractions.
Zhang W; Leighl N; Zawisza D; Moore MJ; Chen EX
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Dec; 829(1-2):45-9. PubMed ID: 16226062
[TBL] [Abstract][Full Text] [Related]
15. Metabolism of GTI-2040, a phosphorothioate oligonucleotide antisense, using ion-pair reversed phase high performance liquid chromatography (HPLC) coupled with electrospray ion-trap mass spectrometry.
Wei X; Dai G; Liu Z; Cheng H; Xie Z; Marcucci G; Chan KK
AAPS J; 2006; 8(4):E743-55. PubMed ID: 17285740
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.
Raynaud FI; Orr RM; Goddard PM; Lacey HA; Lancashire H; Judson IR; Beck T; Bryan B; Cotter FE
J Pharmacol Exp Ther; 1997 Apr; 281(1):420-7. PubMed ID: 9103525
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats.
Geary RS; Watanabe TA; Truong L; Freier S; Lesnik EA; Sioufi NB; Sasmor H; Manoharan M; Levin AA
J Pharmacol Exp Ther; 2001 Mar; 296(3):890-7. PubMed ID: 11181921
[TBL] [Abstract][Full Text] [Related]
18. Biodistribution of 68Ga-labelled phosphodiester, phosphorothioate, and 2'-O-methyl phosphodiester oligonucleotides in normal rats.
Lendvai G; Velikyan I; Bergström M; Estrada S; Laryea D; Välilä M; Salomäki S; Långström B; Roivainen A
Eur J Pharm Sci; 2005 Sep; 26(1):26-38. PubMed ID: 15941654
[TBL] [Abstract][Full Text] [Related]
19. 2'-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro.
Yoo BH; Bochkareva E; Bochkarev A; Mou TC; Gray DM
Nucleic Acids Res; 2004; 32(6):2008-16. PubMed ID: 15064360
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system.
Wu D; Boado RJ; Pardridge WM
J Pharmacol Exp Ther; 1996 Jan; 276(1):206-11. PubMed ID: 8558431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
